drugset / Trial / NCT00736931

Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam

NCT00736931

Phase 1 Completed 20 enrolled UCB Pharma
RandomizedCrossoverDouble-blindBasic science

Summary

The primary objective of the study is to evaluate the neurocognitive effects of brivaracetam

Timeline

Start
2008-07
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Brivaracetam Small molecule 10 mg
Comparator Levetiracetam Other / unclassified 500 mg
Comparator Lorazepam Small molecule 2 mg

Indications